Vismodegib
| Status | Pipeline |
| Development phase | Initial stage |
| Therapeutic cat. | Oncology |
| Polymorphic form | |
| CAS No. | 879085-55-9 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | 5 |
| Samples | Q4 2024 |
Drug description
Vismodegib is used in adults to treat basal cell carcinoma that has spread to other parts of the body (metastatic), or that has come back after surgery, or cannot be treated with surgery or radiation.
Polpharma API
- Samples availability: Q4 2024
- Production facility suitable for ANVISA, FDA and European requirements
- High purity product in accordance to ICH M7 requirements
- Straightforward and cost effective process
- Bask integration with 4 in-house steps
- High quality of the key intermediate sources
- Production in brand new facility with state-of-the-art equipment
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
